{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T15:17:46Z","timestamp":1767626266638,"version":"build-2065373602"},"reference-count":53,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: The discrepancy between the number of potential available kidneys and the number of patients listed for kidney transplant continues to widen all over the world. The transplant of kidneys from hepatitis C virus (HCV)-infected donors into HCV na\u00efve recipients has grown recently because of persistent kidney shortage and the availability of direct-acting antiviral agents. This strategy has the potential to reduce both waiting times for transplant and the risk of mortality in dialysis. Aim: We made an extensive review of the scientific literature in order to review the efficacy and safety of kidney transplant from HCV-viremic donors into HCV na\u00efve recipients who received early antiviral therapy with direct-acting antiviral agents (DAAs). Results: Evidence has been rapidly accumulated on this topic and some reports have been published (n = 11 studies, n = 201 patients) over the last three years. Various combinations of DAAs were administered\u2014elbasvir\/grazoprevir (n = 38), glecaprevir\/pibrentasvir (n = 110), and sofosbuvir-based regimens (n = 53). DAAs were initiated in a range between a few hours before renal transplant (RT) to a median of 76 days after RT. The sustained virological response (SVR) rate was between 97.5% and 100%. A few severe adverse events (SAEs) were noted including fibrosing cholestatic hepatitis (n = 3), raised serum aminotransferase levels (n = 11), and acute rejection (n = 7). It remains unclear whether the AEs were related to the transmission of HCV, the use of DAAs, or kidney transplant per se. It appears that the frequency of AEs was greater in those studies where DAAs were not given in the very early post-kidney transplant phase. Conclusions: The evidence gathered to date encourages the expansion of the kidney donor pool with the adoption of HCV-infected donor organs. We suggest that kidney transplants from HCV-viremic kidneys into HCV-uninfected recipients should be made in the context of research protocols. Many of the studies reported above were externally funded and we need research generating \u201creal-world\u201d evidence. The recent availability of pangenotypic combinations of DAAs, which can be given even in patients with eGFR &lt; 30\/min\/1.73 m2, will promote the notion that HCV-viremic donors are a significant resource for kidney transplant.<\/jats:p>","DOI":"10.3390\/pharmaceutics13040496","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T10:34:12Z","timestamp":1617705252000},"page":"496","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Updated View on Kidney Transplant from HCV-Infected Donors and DAAs"],"prefix":"10.3390","volume":"13","author":[{"given":"Fabrizio","family":"Fabrizi","sequence":"first","affiliation":[{"name":"Division of Nephrology, Dialysis and Kidney Transplant, Ca\u2019 Granda IRCCS Foundation and Maggiore Policlinico Hospital, 20137 Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Cerutti","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Dialysis and Kidney Transplant, Ca\u2019 Granda IRCCS Foundation and Maggiore Policlinico Hospital, 20137 Milano, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo M.","family":"Alfieri","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Dialysis and Kidney Transplant, Ca\u2019 Granda IRCCS Foundation and Maggiore Policlinico Hospital, 20137 Milano, Italy"},{"name":"Department of Clinical Sciences and Community Health, University of Milan, 20137 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piergiorgio","family":"Messa","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Dialysis and Kidney Transplant, Ca\u2019 Granda IRCCS Foundation and Maggiore Policlinico Hospital, 20137 Milano, Italy"},{"name":"Department of Clinical Sciences and Community Health, University of Milan, 20137 Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrneph.2015.5","article-title":"Hepatitis C and its impact on renal transplantation","volume":"2","author":"Morales","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_2","first-page":"S71","article-title":"Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients","volume":"2","author":"Sise","year":"2018","journal-title":"Hemodialysis Int."},{"key":"ref_3","unstructured":"US Department of Health and Human Services, and Health Resources and Services Administration (HRSA) (2021, January 31). Organ Procurement Transplant Network. National Data, Available online: https:\/\/optn.transplant.hrsa.gov\/data\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jvh.12148","article-title":"Meta-analysis of observational studies: Hepatitis C and survival after renal transplant","volume":"2","author":"Fabrizi","year":"2014","journal-title":"J. Viral. Hepat."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0272-6386(03)00024-6","article-title":"Hepatitis C- associated tubulo interstitial injury","volume":"2","author":"Kasuno","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hep.510290123","article-title":"Impact of hepatitis B and C virus on kidney transplantation outcome","volume":"2","author":"Mathurin","year":"1999","journal-title":"Hepatology"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group (2018). KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. Kidney Int. Suppl., 2, S91\u2013S165.","DOI":"10.1016\/j.kisu.2018.06.001"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1007\/s10620-015-3801-y","article-title":"Hepatitis C virus infection increases the risk of developing chronic kidney disease: A systematic review and meta-analysis","volume":"2","author":"Fabrizi","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_9","first-page":"606","article-title":"The impact of renal transplantation on survival in hepatitis C positive end-stage renal disease patients","volume":"2","author":"Knoll","year":"1997","journal-title":"Am. J. Kidney Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1600-6143.2010.03091.x","article-title":"Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients","volume":"2","author":"Kucirka","year":"2010","journal-title":"Am. J. Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Duerr, M., Liefeldt, L., Friedersdorff, F., Choi, M., Ollinger, R., Hofmann, J., Budde, K., Schrezenmeier, E., and Halleck, F. (2021). Pan-genotype pre-exposure prophylaxis (PrEP) allows transplantation of HCV \u2013positive donor kidneys to negative transplant recipients. J. Clin. Med., 2.","DOI":"10.3390\/jcm10010089"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/039139880903200502","article-title":"Current status on renal transplantation from HCV positive donors","volume":"2","author":"Fabrizi","year":"2009","journal-title":"Int. J. Artif. Organs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.nefro.2019.01.002","article-title":"Hepatitis C and kidney transplant. The eradication time has arrived","volume":"2","author":"Esforzado","year":"2019","journal-title":"Nefrologia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1111\/j.1600-6143.2010.03280.x","article-title":"Long-term experience with kidney transplantation from hepatitis C positive donors into hepatitis C-positive recipients","volume":"2","author":"Morales","year":"2010","journal-title":"Am. J. Transplant."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ckj\/sfx048","article-title":"Effect of kidney donor hepatitis C virus serostatus on renal transplant recipient and allograft outcome","volume":"2","author":"Cohen","year":"2017","journal-title":"Clin. Kidney J."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Gupta, G., Kang, L., Yu, J., Limkemann, A., Garcia, V., Bandyopadyay, D., Kumar, D., Fattah, H., Levy, M., and Cotterell, A. (2017). Long-term outcomes and transmission rates in hepatitis C virus positive donor to hepatitis C virus negative kidney transplant recipients: Analysis of United States national data. Clin. Transplant., 2.","DOI":"10.1111\/ctr.13055"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1177\/003335491312800403","article-title":"PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation","volume":"2","author":"Seem","year":"2013","journal-title":"Public Health Rep."},{"key":"ref_18","unstructured":"Hepatitis C Online (2021, January 15). Diagnosis of Acute HCV Infection. Available online: https:\/\/www.hepatitisc.uw.edu\/go\/screening-diagnosis\/acute-diagnosis\/core-concept\/all."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1111\/ajt.14381","article-title":"The American Society of Transplantation consensus conference on the use of hepatitis C viremic donors in solid organ transplantation","volume":"2","author":"Levitsky","year":"2017","journal-title":"Am. J. Transplant."},{"key":"ref_20","unstructured":"(2020, August 27). AASLD (American Association for the Study of Liver Diseases) and IDSA (Infectious Disease Society of America): HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis, C. Available online: http:\/\/hcvguidelines.org."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, pharmacodynamics, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir","volume":"2","author":"Kirby","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"ref_22","unstructured":"Center for Drug Evaluation and Research (2020, July 02). Sofosbuvir Clinical Pharmacology and Biopharmaceutics Review, Available online: https:\/\/www.ccessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204671Orig1s000ClinPharmR."},{"key":"ref_23","first-page":"85","article-title":"Sofosbuvir antiviral therapy in HCV patients with severe renal failure","volume":"2","year":"2017","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"2","author":"Saxena","year":"2016","journal-title":"Liver Int."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end stage renal disease undergoing dialysis","volume":"2","author":"Borgia","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"E225","DOI":"10.1016\/S0618-8278(19)30419-0","article-title":"Ledipasvir\/sofosbuvir for 8, 12, or 24 weeks is safe and effective in patients undergoing dialysis","volume":"2","author":"Chuang","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0041-1345(00)01572-4","article-title":"Kidney transplantation from a donor who is HCV antibody positive and HCV RNA negative","volume":"2","author":"Tokumoto","year":"2000","journal-title":"Transplant. Proc."},{"key":"ref_28","first-page":"773","article-title":"Successful treatment of chronic HCV infection should not preclude kidney donation to an HCV negative recipient","volume":"2","author":"Cruzado","year":"2013","journal-title":"Am. J. Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ekir.2016.09.058","article-title":"Transplantation of renal allografts from organ donors reactive for HCV antibodies to HCV-negative recipients: Safety and clinical outcome","volume":"2","author":"Nowak","year":"2016","journal-title":"Kidney Int. Rep."},{"key":"ref_30","first-page":"2451","article-title":"Transplantation of hepatitis C virus (HCV) antibody positive, nucleic acid test negative donor kidneys to HCV negative patients frequently results in seroconversion but not HCV viremia","volume":"2","author":"Volk","year":"2018","journal-title":"Am. J. Transplant."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e13598","DOI":"10.1111\/ctr.13598","article-title":"Use of HCV Ab+\/NAT\u2212 donors in HCV na\u00efve renal transplant recipients to expand the kidney donor pool","volume":"2","author":"Dao","year":"2019","journal-title":"Clin. Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/tri.13410","article-title":"Renal transplantation from seropositive hepatitis C virus donors to seronegative recipients in Spain: A prospective study","volume":"2","author":"Franco","year":"2019","journal-title":"Transpl. Int."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e13761","DOI":"10.1111\/ctr.13761","article-title":"Liver, simultaneous liver-kidney, and kidney transplantation from hepatitis C-positive donors in hepatitis C-negative recipients: A single-center study","volume":"2","author":"Crismale","year":"2020","journal-title":"Clin. Transplant."},{"key":"ref_34","unstructured":"Wolfe, C., Tlusty, S., Veve, G., Bag, R., Berry, G., Bucio, J., Danziger-Isakov, L., Florescu, D., Goldberg, D., and Ho, C. (2018). Donor Derived Transmissions in 2016-107: Analysis of the OPTN ad hoc Disease Transmission Advisory Committee (DTAC), American Transplant Congress. [abstract 565]."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Wang, J., Gustafson, S., Skeans, M., Lake, J., Kim, W., Kasiske, B., Israni, A., and Hart, A. (2020). OPTH\/SRTR 2018 Annual Data Report. Am. J. Transplant.","DOI":"10.1111\/ajt.15679"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1111\/ajt.14386","article-title":"Utilization of organs from donors according to hepatitis C antibody and nucleic acid testing status: Time for change","volume":"2","author":"King","year":"2017","journal-title":"Am. J. Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/ajt.15355","article-title":"Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States","volume":"2","author":"Bowring","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to non-infected recipients. An open-label nonrandomized trial","volume":"2","author":"Durand","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/M18-0749","article-title":"Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: An open-label nonrandomized trial","volume":"2","author":"Reese","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMc1705221","article-title":"Trial of transplantation of HCV-infected kidneys into uninfected recipients","volume":"2","author":"Goldberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_41","first-page":"e13146","article-title":"Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients","volume":"2","author":"Gackler","year":"2019","journal-title":"Transpl. Infect. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ekir.2020.01.001","article-title":"Pre emptive treatment with elbasvir and grazoprevir for hepatitis C viremic donor to uninfected recipient kidney transplantation","volume":"2","author":"Sise","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1681\/ASN.2020050686","article-title":"Multicenter study to transplant hepatitis C-infected kidneys (MYTHIC): An open-label study of combined glecaprevir and pibrentasvir to treat recipients of transplanted kidneys from deceased donors with hepatitis C virus infection","volume":"2","author":"Sise","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1111\/ajt.15530","article-title":"Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: Single-center experience","volume":"2","author":"Molnar","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S2468-1253(20)30081-9","article-title":"Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: A phase 3, single-centre, open-label study","volume":"2","author":"Feld","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.31011","article-title":"Hepatitis C virus NAT-positive solid organ allografts transplanted into hepatitis C virus \u2013negative recipients: A real-world experience","volume":"2","author":"Kapila","year":"2020","journal-title":"Hepatology"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Terrault, N., Burton, J., Ghobrial, M., Verna, E., Bayer, J., Klein, C., Victor, D., Moan, S., Trotter, J., and Dodge, J. (2020). Prospective multicenter study of early antiviral therapy in liver and kidney transplant recipients of HCV-viremic donors. Hepatology.","DOI":"10.1002\/hep.31551"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1503\/cjs.023811","article-title":"Research funded by the industry","volume":"2","author":"Harvey","year":"2011","journal-title":"Can. J. Surg."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/ajt.15664","article-title":"Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients","volume":"2","author":"Gupta","year":"2020","journal-title":"Am. J. Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/TP.0000000000003014","article-title":"Liver and kidney recipient selection of HCV-viremic donors- meeting consensus report from the 2019 controversies in transplantation","volume":"2","author":"Burton","year":"2020","journal-title":"Transplantation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.30933","article-title":"Utilization of hepatitis C virus viremic organs for HCV negative recipients: Is practice speeding past the evidence?","volume":"2","author":"Verna","year":"2020","journal-title":"Hepatology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/ajt.15152","article-title":"Transplantation of HCV-infected organs into uninfected recipients: Advance with caution","volume":"2","author":"Wadei","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1681\/ASN.2019050462","article-title":"National trends in utilization and 1-year outcomes with transplantation of HCV-viremic kidneys","volume":"2","author":"Potluri","year":"2019","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/4\/496\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:26:21Z","timestamp":1760361981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/4\/496"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,6]]},"references-count":53,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["pharmaceutics13040496"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13040496","relation":{},"ISSN":["1999-4923"],"issn-type":[{"type":"electronic","value":"1999-4923"}],"subject":[],"published":{"date-parts":[[2021,4,6]]}}}